Mie Torii1, Motomu Hashimoto2, Akiko Hanai1, Takao Fujii2, Moritoshi Furu2, Hiromu Ito2,3, Ryuji Uozumi4, Masahide Hamaguchi5, Chikashi Terao6, Wataru Yamamoto2,7, Miyabi Uda1, Kazuko Nin1, Satoshi Morita4, Hidenori Arai8, Tsuneyo Mimori2,9. 1. a Department of Human Health Sciences, Graduate School of Medicine , Kyoto University , Kyoto , Japan. 2. b Department of the Control for Rheumatic Diseases, Graduate School of Medicine , Kyoto University , Kyoto , Japan. 3. c Department of Orthopedic Surgery, Graduate School of Medicine , Kyoto University , Kyoto , Japan. 4. d Department of Biomedical and Bioinformatics, Graduate School of Medicine , Kyoto University , Kyoto , Japan. 5. e Department of Endocrinology and Metabolism, Graduate School of Medicine , Kyoto Prefectural University of Medicine , Kyoto , Japan. 6. f Unit of Human Disease Genomics Center for Genomic Medicine, Graduate School of Medicine , Kyoto University , Kyoto , Japan. 7. g Department of Health Information Management , Kurashiki Sweet Hospital , Kurashiki , Japan. 8. h National Center for Geriatrics and Gerontology , Obu , Japan. 9. i Department of Rheumatology and Clinical Immunology, Graduate School of Medicine , Kyoto University , Kyoto , Japan.
Abstract
Objectives: Sarcopenia is characterized by loss of muscle strength and mass, leading to falls and adverse health outcomes. Our aim was to determine the prevalence of sarcopenia in patients with rheumatoid arthritis (RA) and to identify factors associated with sarcopenia in these patients. Methods: A cross-sectional study of 388 consecutive women with RA was conducted, assessing muscle mass and strength, and walking speed. Falls and bone fractures sustained over the prior year were evaluated. The association between sarcopenia and RA characteristics, falls, and bone fractures was evaluated using logistic regression analyses. Results: The prevalence of sarcopenia was 37.1% (14.7%, severe sarcopenia; 22.4%, sarcopenia), with 49.0% classified as having low muscle mass. The incidence of falls, fractures, and lower bone mineral density was higher in patients with than without sarcopenia. Age, RA duration, Steinbrocker's stage, the high Mini-Nutritional Assessment-Short Form score and the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) were independent factors associated with sarcopenia. Conclusion: We confirmed that sarcopenia develops in a significant proportion of patients with RA. Age, longer disease duration, joint destruction and malnutrition were positively associated with sarcopenia, with the use of bDMARDs being negatively associated.
Objectives:Sarcopenia is characterized by loss of muscle strength and mass, leading to falls and adverse health outcomes. Our aim was to determine the prevalence of sarcopenia in patients with rheumatoid arthritis (RA) and to identify factors associated with sarcopenia in these patients. Methods: A cross-sectional study of 388 consecutive women with RA was conducted, assessing muscle mass and strength, and walking speed. Falls and bone fractures sustained over the prior year were evaluated. The association between sarcopenia and RA characteristics, falls, and bone fractures was evaluated using logistic regression analyses. Results: The prevalence of sarcopenia was 37.1% (14.7%, severe sarcopenia; 22.4%, sarcopenia), with 49.0% classified as having low muscle mass. The incidence of falls, fractures, and lower bone mineral density was higher in patients with than without sarcopenia. Age, RA duration, Steinbrocker's stage, the high Mini-Nutritional Assessment-Short Form score and the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) were independent factors associated with sarcopenia. Conclusion: We confirmed that sarcopenia develops in a significant proportion of patients with RA. Age, longer disease duration, joint destruction and malnutrition were positively associated with sarcopenia, with the use of bDMARDs being negatively associated.
Authors: Su H Chu; Jing Cui; Jeffrey A Sparks; Bing Lu; Sara K Tedeschi; Cameron B Speyer; LauraKay Moss; Marie L Feser; Lindsay B Kelmenson; Elizabeth A Mewshaw; Jess D Edison; Kevin D Deane; Clary Clish; Jessica Lasky-Su; Elizabeth W Karlson; Karen H Costenbader Journal: Rheumatology (Oxford) Date: 2020-11-01 Impact factor: 7.580
Authors: Fausto Salaffi; Marina Carotti; Andrea Di Matteo; Luca Ceccarelli; Sonia Farah; Catalina Villota-Eraso; Marco Di Carlo; Andrea Giovagnoni Journal: Radiol Med Date: 2022-09-20 Impact factor: 6.313
Authors: Aqeel M Alenazi; Mohammed M Alshehri; Bader A Alqahtani; Ahmad D Alanazi; Saad M Bindawas Journal: Clin Rheumatol Date: 2020-08-27 Impact factor: 2.980